The National Health Service in England has become the first healthcare system in Europe to widely roll out cladribine, a take-at-home tablet for multiple sclerosis (MS) patients. This significant development offers a convenient alternative to hospital-based treatments for thousands of patients with active relapsing-remitting MS. A Treatment Revolution Cladribine, also known by its brand name Mavenclad, requires just 20 days of treatment spread over four years. This marks a dramatic shift from traditional MS therapies that involve regular hospital visits, frequent self-injections, and extensive monitoring. “The NHS is proud to be the first healthcare system in Europe to roll out … Continue reading NHS Launches Cladribine: Home MS Treatment with 80% Relapse Reduction